| Structure |
Catalog |
Product Name |
CAS |
E3 Ligase |
Target |
Inquiry |
![2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)-2-oxoethyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile](https://resource.bocsci.com/structure/2632306-21-7.gif) |
BPL-202553 |
2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)-2-oxoethyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile |
2632306-21-7 |
CRBN |
AR |
Inquiry |
|
Molecular Weight: 817.35
Molecular Formula: C44H45ClN8O6
Density: 1.49±0.1 g/cm3
Description: It is a spirocyclic androgen receptor protein degrader used to treat prostate cancer.
|
![2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile](https://resource.bocsci.com/structure/2632306-23-9.gif) |
BPL-202554 |
2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile |
2632306-23-9 |
CRBN |
AR |
Inquiry |
|
Molecular Weight: 817.35
Molecular Formula: C44H45ClN8O6
Density: 1.49±0.1 g/cm3
Description: It is a spirocyclic androgen receptor protein degrader used to treat prostate cancer.
|
![2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile](https://resource.bocsci.com/structure/2632306-24-0.gif) |
BPL-202555 |
2-Chloro-4-((3S)-8-(4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-5-oxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)acetyl)piperazine-1-carbonyl)phenyl)-3-methyl-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile |
2632306-24-0 |
CRBN |
AR |
Inquiry |
|
Molecular Weight: 803.36
Molecular Formula: C44H47ClN8O5
Density: 1.46±0.1 g/cm3
Description: It is a spirocyclic androgen receptor protein degrader used to treat prostate cancer.
|
 |
BPL-202556 |
SJ000988497 |
2595365-41-4 |
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 688.75
Molecular Formula: C36H36N10O5
Density: 1.51±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
 |
BPL-202557 |
SJ000986420 |
|
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 673.78
Molecular Formula: C37H39N9O4
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
 |
BPL-202558 |
SJ000988500 |
2595365-45-8 |
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 716.80
Molecular Formula: C38H40N10O5
Density: 1.46±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
 |
BPL-202559 |
SJ000988498 |
2595365-47-0 |
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 674.72
Molecular Formula: C35H34N10O5
Density: 1.53±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
 |
BPL-202560 |
SJ000988499 |
2595365-49-2 |
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 702.78
Molecular Formula: C37H38N10O5
Density: 1.48±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
 |
BPL-202561 |
SJ000986340 |
2595365-51-6 |
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 704.75
Molecular Formula: C36H36N10O6
Density: 1.52±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
 |
BPL-202562 |
SJ000986050 |
2595365-53-8 |
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 925.01
Molecular Formula: C46H56N10O11
Density: 1.41±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
 |
BPL-202563 |
SJ000986048 |
2595365-81-2 |
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 880.96
Molecular Formula: C44H52N10O10
Density: 1.43±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
 |
BPL-202564 |
SJ000986049 |
2595365-55-0 |
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 836.91
Molecular Formula: C42H48N10O9
Density: 1.44±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
 |
BPL-202565 |
SJ001005328 |
2595365-75-4 |
CRBN |
JAK2 |
Inquiry |
|
Molecular Weight: 767.85
Molecular Formula: C41H41N11O5
Density: 1.52±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Janus kinase as a therapeutic strategy for cancer and rheumatoid arthritis.
|
![(7S)-7-(1-(1-(14-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide](https://resource.bocsci.com/structure/2599844-75-2.gif) |
BPL-202566 |
(7S)-7-(1-(1-(14-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
2599844-75-2 |
CRBN |
BTK |
Inquiry |
|
Molecular Weight: 988.07
Molecular Formula: C50H57N11O11
Density: 1.49±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
|
![(7S)-7-(1-(1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide](https://resource.bocsci.com/structure/2599844-76-3.gif) |
BPL-202567 |
(7S)-7-(1-(1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
2599844-76-3 |
CRBN |
BTK |
Inquiry |
|
Molecular Weight: 1032.12
Molecular Formula: C52H61N11O12
Density: 1.47±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
|
![(7S)-7-(1-(1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide](https://resource.bocsci.com/structure/2599844-77-4.gif) |
BPL-202568 |
(7S)-7-(1-(1-(17-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaheptadecyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
2599844-77-4 |
CRBN |
BTK |
Inquiry |
|
Molecular Weight: 1032.12
Molecular Formula: C52H61N11O12
Density: 1.47±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
|
![(7S)-7-(1-(1-(20-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18-hexaoxaicosyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide](https://resource.bocsci.com/structure/2599844-78-5.gif) |
BPL-202569 |
(7S)-7-(1-(1-(20-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18-hexaoxaicosyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
2599844-78-5 |
CRBN |
BTK |
Inquiry |
|
Molecular Weight: 1076.18
Molecular Formula: C54H65N11O13
Density: 1.45±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
|
![(7S)-7-(1-(1-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-2-oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide](https://resource.bocsci.com/structure/protac3087.gif) |
BPL-202570 |
(7S)-7-(1-(1-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-2-oxoethoxy)ethoxy)ethyl)-1H-1,2,3-triazole-4-carbonyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
|
CRBN |
BTK |
Inquiry |
|
Molecular Weight: 913.95
Molecular Formula: C46H47N11O10
Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
|
![(7S)-7-(1-(3-(4-(4-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)phenyl)propanoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide](https://resource.bocsci.com/structure/2599845-02-8.gif) |
BPL-202571 |
(7S)-7-(1-(3-(4-(4-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)phenyl)propanoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
2599845-02-8 |
CRBN |
BTK |
Inquiry |
|
Molecular Weight: 890.01
Molecular Formula: C50H51N9O7
Density: 1.47±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
|
![(7S)-7-(1-(4-(4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)acetamido)phenyl)butanoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide](https://resource.bocsci.com/structure/2599845-20-0.gif) |
BPL-202572 |
(7S)-7-(1-(4-(4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)acetamido)phenyl)butanoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide |
2599845-20-0 |
CRBN |
BTK |
Inquiry |
|
Molecular Weight: 891.99
Molecular Formula: C49H49N9O8
Density: 1.48±0.1 g/cm3
Description: It is a PROTAC that mediates the degradation of Bruton's tyrosine kinase as a therapeutic strategy for cancer.
|
